Sentynl Therapeuticsincis A Specialty Pharmaceutical Company Based In San Diegocaliforniaestablished In August 2011The Company Is Committed To Enhancing Patient Care Through Innovative Therapeuticsparticularly For Rare Diseasessentynl Therapeutics Focuses On Developing Novel Biopharmaceutical Medicines That Aim To Improve The Lives Of Patients And Their Caregivers One Of The Company S Key Products Is Nulibryfosdenopterin Which Is Designed To Reduce The Risk Of Mortality In Patients With A Specific Rare Conditionsentynl Therapeutics Acquired The Rights To Manufacture And Distribute Nulibry In March 2022The Company Distributes Its Products Through Wholesale And Specialty Retail Distributorsprimarily Serving Healthcare Providers And Patients Affected By Rare Diseasessentynl Therapeutics Operates Under Principles Of Integritytransparencyaccountabilityand Compassionstriving To Make A Meaningful Impact In The Field Of Rare Disease Treatment
United States
